Animal models of maple syrup urine disease

Journal of Inherited Metabolic Disease

Volumn 32, Issue 2, 2009, Pages 229-246

  Skvorak, K J ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; DIHYDROLIPOAMIDE DEHYDROGENASE;

AMINO ACID METABOLISM; ARTICLE; BRAIN; CLINICAL EFFECTIVENESS; COW; DIET RESTRICTION; DISEASE MODEL; GENETIC HETEROGENEITY; GENETIC SIMILARITY; HEMODIALYSIS; HUMAN; KNOCKOUT MOUSE; LIVER STRUCTURE; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE; MOLECULAR GENETICS; MUSCLE ATROPHY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARALYSIS; PATHOPHYSIOLOGY; PHENOTYPE; SEIZURE; TRANSGENIC MOUSE; TREATMENT INDICATION; WEIGHT REDUCTION;

3-METHYL-2-OXOBUTANOATE DEHYDROGENASE (LIPOAMIDE); AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; BRAIN; CATTLE; DIET; DISEASE MODELS, ANIMAL; LIVER; MAPLE SYRUP URINE DISEASE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 64449083415     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1086-z     Document Type: Article

References (125)

1. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Intracellular compartments and protein sorting. In: Anderson MS, Singer B, eds. Molecular Biology of the Cell. New York: Garland Science.
2. Anthony JC, Anthony TG, Kimball SR, Jefferson LS (2001) Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine. J Nutr 131: 856S-860S.
3. Araújo PR, Wassermann GF, Tallini K, et al (2001) Reduction of large neutral amino acids in plasma and brain in hyperleucinemic rats. Neurochem Int 38: 529-537. doi: 10.1016/S0197-0186(00)00100-5.
4. Beal MF (2001) Experimental models of Parkinsons's disease. Nat Rev Neurosci 2: 325-334. doi: 10.1038/35072550.
5. Beal MF, Brouillet E, Jenkins BG, et al (1993) Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192.
6. Blair PV, Kobayashi R, Edwards HM, Shay NF, Baker DH, Harris RA (1999) Dietary thiamin level influences levels of its diphosphate form and thiamin-dependent enzymic activities of rat liver. J Nutr 129: 641-648.
7. Bodner-Leidecker A, Wendel U, Saudubray JM, Schadewaldt P (2000) Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantation. J Inherit Metab Dis 23: 805-818. doi: 10.1023/A:1026708618507.
8. Calingasana NY, Hoa DJ, Willea EJ, et al (2008) Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience 153(4): 986-996. doi: 10.1016/ j.neuroscience.2008.02.071.
9. Cerna L, Wenchich L, Hansikova H, et al (2001) Novel mutations in a boy with dihydrolipoamide dehydrogenase deficiency. Med Sci Monit 7: 1319-1325.
10. Chi C, Tsai C, Chen L, et al (2003) Maple syrup urine disease in the Austronesian aboriginal tribe Paiwan of Taiwan: A novel DBT (E2) gene 47 kb founder deletion caused by a nonhomologous recombination between LINE-1 and Alu and the carrier-frequency determination. Eur J Hum Genet 11(12): 931-936. doi: 10.1038/sj.ejhg.5201069.
11. Chicco AG, Adibi SA, Liu WQ, Morris SMJ, Paul HS (1994) Regulation of gene expression of branched-chain keto acid dehydrogenase complex in primary cultured hepatocytes by dexamethasone and a cAMP analog. J Biol Chem 269(30): 19427.
12. Chuang DT, Shih VE (1995) Maple syrup urine disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1239-1277.
13. Chuang DT, Shih VE (2001) Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1971-2005.
14. Chuang DT, Chuang JL, Wynn RM (2006) Lessons from genetic disorders of branched-chain amino acid metabolism. J Nutr 136(Supplement 1): 243S-249S.
15. Chuang JL, Cox RP, Chuang DT (1996) Maple syrup urine disease: The E1beta gene of human branched-chain alpha-ketoacid dehydrogenase complex has 11 rather than 10 exons and the 3-prime UTR in one of the two E1-beta mRNAs arises from intronic sequences. Am J Hum Genet 58: 1373-1377.
16. Chuang JL Cox RP, Chuang DT (1997) E2 Transacylase-deficient (Type II) maple syrup urine disease: Aberrant splicing of E2 mRNA caused by internal intronic deletions and association with thiamine-responsive phenotype. J Clin Invest 100(3): 736-744. doi: 10.1172/JCI119586.
17. Chuang DT, Davie JR, Wynn RM, Chuang JL, Koyata H, Cox RP (1995) Molecular basis of maple syrup urine disease and stable correction by retroviral gene transfer. J Nutr 125(6 Supplement): 1766S-1772S.
18. Chuang J, Wynn R, Moss C, et al (2004) Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: A proposed mechanism for the thiamin-responsive phenotype. J Biol Chem 279(17): 17792-17800. doi: 10.1074/jbc.M313879200.
19. Copeland S, Tuerck J, Paradise L (2004) Maple Syrup Urine Disease in NW Regional Newborn Screening Program. Portland OR: OHSU.
20. Costa-Pinto FA, Basso AS, Britto LR, Malucelli BE, Russo M (2005) Avoidance behavior and neural correlates of allergen exposure in a murine model of asthma. Brain Behav Immun 19(1): 52-60. doi: 10.1016/ j.bbi.2004.02.005.
21. Cox RP, Chuang DT (1993) Maple syrup urine disease: Clinical and molecular genetic considerations. In: Rosenberg R et al, eds. The Molecular and Genetic Basis for Neurological Disease. Boston: Butterworth-Heinemann, 189-207.
22. Crome L, Dutton G, Ross CF (1961) Maple syrup urine disease. J Pathol Bacteriol 81: 379-384. doi: 10.1002/path.1700810209.
23. Damuni Z, Merryfield ML, Humphreys JS, Reed LJ (1984) Purification and properties of branched-chain alpha-keto acid dehydrogenase phosphatase from bovine kidney. Proc Natl Acad Sci U S A 81: 4335-4338. doi: 10.1073/ pnas.81.14.4335.
24. Dancis J, Hutzler J, Levitz M (1960) Metabolism of the white blood cells in maple syrup urine disease. Biochim Biophys Acta 43: 342-343. doi: 10.1016/0006-3002(60)90448-0.
25. Danner DJ, Doering CB (1998) Human mutations affecting branched chain α-ketoacid dehydrogenase. Front Biosci 3: D517-524.
26. Danner DJ, Armstrong N, Heffelfinger SC, Sewell ET, Priest JH and Elsas LJ (1985) Absence of branched chain acyltransferase as a cause of maple syrup urine disease. J Clin Invest 75: 858-860. doi: 10.1172/JCI111783.
27. Danner DJ, Litwer S, Herring WJ, Pruckler J (1989) Construction and nucleotide sequence of a cDNA encoding the full-length preprotein for human branched chain acyltransferase. J Biol Chem 264: 7742-7746.
28. Dennis JA, Healy PJ (1999) Definition of the mutation responsible for maple syrup urine disease in Poll Shorthorns and genotyping Poll Shorthorns and Poll Herefords for maple syrup urine disease alleles. Res Vet Sci 67(1): 1-6. doi: 10.1053/rvsc.1998.0296.
29. Dodd PR, Williams SH, Gundlach AL, et al (1992) Glutamate and gamma-aminobutyric acid neurotransmitter systems in the acute phase of maple syrup urine disease and citrullinemia encephalopathies in newborn calves. J Neurochem 59: 582-590. doi: 10.1111/j.1471-4159.1992.tb09409.x.
30. Duran M, Wadman SK (1985) Thiamine-responsive inborn errors of metabolism. J Inherit Metab Dis 8(Supplement 1): 70-75. doi: 10.1007/ BF01800663.
31. Duran M, Tielens AGM, Wadman SK, Stigter JCM, Kleijer WJ (1978) Effects of thiamine in a patient with a variant form branched-chain ketoaciduria. Acta Paediatr Scand 67: 367-372. doi: 10.1111/ j.1651-2227.1978.tb16336.x.
32. Edelmann L, Wasserstein MP, Kornreich R, Sansaricq C, Snyderman S, Diaz GA (2001) Maple Syrup Urine Disease: Identification of carrier frequency determination of a novel founder mutation in the Ashkenazi Jewish population. Am J Hum Genet 69(4): 863-868.
33. Eisenstein AB, Strack I, Gallo-Torres H, Georgiadis A, Miller ON (1979) Increased glucagon secretion in protein-fed rats: Lack of relationship to plasma amino acids. Am J Physiol 236(1): E20-E27.
34. Elpeleg ON, Shaag A, Glustein JZ, Anikster Y, Joseph A, Saada A (1997) Lipoamide dehydrogenase deficiency in Ashkenazi Jews: An insertion mutation in the mitochondrial leader sequence. Hum Mutat 10: 256-257. doi: 10.1002/(SICI)1098-1004(1997)10:3<256::AID-HUMU16>3.0.CO;2-Z.
35. Fair JH, Caims BA, LaPaglia MA, et al (2005) Correction of factor IX deficiency in mice by embryonic stem cells differentiated in vitro. PNAS 102(8): 2958-2963. doi: 10.1073/pnas.0409840102.
36. Falk MC, Knight JF, Roy LP, et al (1994) Continuous venovenous haemofiltration in the acute treatment of inborn errors of metabolism. Pediatr Nephrol 8(3): 330-333. doi: 10.1007/BF00866350.
37. Fisher CW, Lau KS, Fisher CR, Wynn RM, Cox RP, Chuang DT (1991) A 17-bp insertion and a phe215-to-cys missense mutation in the dihydrolipoyl (e2) mRNA from a thiamine-responsive maple syrup urine disease patient WG-34. Biochem Biophys Res Commun 174: 804-809. doi: 10.1016/ 0006-291X(91)91489-Y.
38. Gietzen DW, Magrum LJ (2001) Molecular mechanisms in the brain involved in the anorexia of branched-chain amino acid deficiency. J Nutr 131: 851s-855s.
39. Gooderham PA, Gagnon RF, Gill K (2004) Attenuation of the alcohol preference of C57BL/6 mice during chronic renal failure. J Lab Clin Med 143(5): 292-300. doi: 10.1016/j.lab.2004.01.010.
40. Gortner L, Leupold D, Pohlandt F, Bartmann P (1989) Peritoneal dialysis in the treatment of metabolic crises caused by inherited disorders of organic and amino acid metabolism. Acta Paediatr Scand 78: 706-711. doi: 10.1111/j.1651-2227.1989.tb11130.x.
41. Grafakou O, Oexle K, Van den Heuvel L, et al (2003) Leigh syndrome due to compound heterozygosity of dihydrolipoamide dehydrogenase gene mutations: Description of the first E3 splice site mutation. Eur J Pediatr 162: 714-718. doi: 10.1007/s00431-003-1282-z.
42. Hammersen G, Wille L, Schmidt H, Lutz P, Bickel H (1978) Maple syrup urine disease: Treatment of the acutely ill newborn. Eur J Pediatr 129: 157-165. doi: 10.1007/BF00442159.
43. Harding CO, Gillingham MB, Hamman K, et al (2006) Complete correction of hyperphenylalaninemia following liver-directed recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther 13(5): p457-462. doi: 10.1038/sj.gt.3302678.
44. Harper AE, Miller RH, Block KP (1984) Branched-chain amino acid metabolism. Annu Rev Nutr 4: 409-454.
45. Harper PA, Healy PJ, Dennis JA (1986) Maple syrup urine disease as a cause of spongiform encephalopathy in calves. Vet Rec 119(3): 62-65.
46. Harper PA, Dennis JA, Healy PJ, Brown GK (1989) Maple syrup urine disease in calves: A clinical pathological and biochemical study. Aust Vet J 66(2): 46-49. doi: 10.1111/j.1751-0813.1989.tb03014.x.
47. Harris RA, Joshi M, Jeoung NH (2004) Mechanisms responsible for regulation of branched-chain amino acid catabolism. Biochem Biophys Res Commun 313(2): 391-396. doi: 10.1016/j.bbrc.2003.11.007.
48. Harris RA, Powell SM, Paxton R, Gillim SE, Nagae H (1985) Physiological covalent regulation of rat liver branched-chain alpha-ketoacid dehydrogenase. Arch Biochem Biophys 243(2): 542-555. doi: 10.1016/ 0003-9861(85)90531-4.
49. Healy PJ, Dennis JA (1994) Molecular heterogeneity for bovine maple syrup urine disease. Anim Genet 25(5): 329-332.
50. Hilliges C, Awiszus D, Wendel U (1993) The intellectual performance of patients with maple syrup urine disease (MSUD). Eur J Pediatr 152: 144-147. doi: 10.1007/BF02072492.
51. Homanics GE, Skvorak K, Ferguson C, Watkins S, Paul HS (2006) Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet 7: 33.
52. Hong YS, Korman SH, Lee J, et al (2003) Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: Possible beneficial effect of vitamin therapy J Inherit Metab Dis 26(8): 816-818. doi: 10.1023/B:BOLI.0000010004.12053.5b.
53. Hutson SM, Hall TR (1993) Identification of the mitochondrial branched chain aminotransferase as a branched chain alpha-keto acid transport protein. J Biol Chem 268(5): 3084-3091.
54. Johnson MT, Yang H-S, Magnuson T, Patel MS (1997) Targeted disruption of the murine dihydrolipoyl dehydrogenase gene (Dld) results in perigastrulation lethality. Proc Natl Acad Sci U S A 94: 14512-14517. doi: 10.1073/pnas.94.26.14512.
55. Jouvet P, Poggi F, Rabier D, et al (1997) Continuous venovenous haemodiafiltration inthe acute phase of neonatal maple syrup urine disease. J Inherit Metab Dis 20(4): 463-472. doi: 10.1023/ A:1005314025760.
56. Kamei A, Takashima S, Chan F, Becker LE (1992) Abnormal dendritic development in maple syrup urine disease. Pediatr Neurol 8: 145-147. doi: 10.1016/0887-8994(92)90038-Z.
57. Kaplan P, Mazur A, Field M, et al (1991) Intellectual outcome inchildren with maple syrup urine disease. J Pediatr 119: 46-50. doi: 10.1016/ S0022-3476(05)81037-6.
58. Kistner A, Gossen M, Zimmermann F, et al (1996) Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93: 10933-10938. doi: 10.1073/ pnas.93.20.10933.
59. Klivenyi P, Starkov AA, Calingasan NY, et al (2004) Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 88: 1352-1360. doi: 10.1046/j.1471-4159.2003.02160.x.
60. Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B (1994) Maple syrup urine disease: Clinical EEG and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 79(1-2): 21-45.
61. Layman DK (2003) The role of leucine in weight loss diets and glucose homeostasis. J Nutr 133: 261S-267S.
62. Le Cam A, Freychet P (1977) Neutral amino acid transport. Characterization of the A and L systems in isolated rat hepatocytes. J Biol Chem 252: 148-156.
63. Lin MC, Chen CH, Fu L, Jan SL, Shu SG, Chi CS (2002) Management of acute decompensation of neonatal maple syrup urine disease with continuous arteriovenous haemofiltration: Report of one case. Acta Paediatr Taiwan 43(5): 281-284.
64. Marshall L, Di George (1981) Maple syrup urine disease in the old order Mennonites. Am J Hum Genet 33: 139a.
65. 13C NMR study. J Neurochem 70: 1001-1008.
66. McMahon Y, MacDonnell RCJ (1990) Clearance of branched chain amino acids by peritoneal dialysis in maple syrup urine disease. Adv Perit Dial 6: 31-34.
67. Menkes J, Hurst P, Craig J (1954) A new syndrome: Progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 14: 462-466.
68. Mizuno Y, Suzuki K, Ohta S (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 96: 49-57. doi: 10.1016/ 0022-510X(90)90056-S.
69. Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI (2002) Diagnosis and treatment of maple syrup urine disease: A study of 36 patients. Pediatrics 109(6): 999-1008. doi: 10.1542/peds.109.6.999.
70. MSUD Family Support Group (2006a) Breakout Session: Teaching Self Care/ Management. MSUD Family Support Group Symposium, Dublin, OH, USA. June 15-17.
71. MSUD Family Support Group (2006b) Group Meet and Greet/Reception. MSUD Family Support Group Symposium, Dublin, OH, USA. June 15-17.
72. Mueller GM, McKenzie LR, Homanics GE, Watkins SC, Robbins PD, Paul HS (1995) Complementation of defective leucine decarboxylation in fibroblasts from a maple syrup urine disease patient by retrovirus-mediated gene transfer. Gene Ther 2(7): 461-468.
73. Nebes VL, Morris SMJ (1988) Regulation of messenger ribonucleic acid levels for five urea cycle enzymes in cultured rat hepatocytes Requirements for cyclic adenosine monophosphate glucocorticoids and ongoing protein synthesis. Mol Endocrinol 2(5): 444-451.
74. Netter JC, Cossarizza G, Narcy C, et al (1994) Mid-term outcome of 2 cases with maple syrup urine disease: Role of liver transplantation in the treatment. Arch Pediatr 1: 730-734.
75. Nissen SL, Abumrad NN (1997) Nutritional role of the leucine metabolite β-hydroxy β-methylbutyrate (HMB). J Nutr Biochem 8: 300-311 doi: 10.1016/S0955-2863(97)00048-X.
76. Nobukuni Y, Mitsubuchi H, Endo F, Matsuda I (1989) Complete primary structure of the transacylase (E2b) subunit of the human branched chain alpha-keto acid dehydrogenase complex. Biochem Biophys Res Commun 161: 1035-1041. doi: 10.1016/0006-291X(89)91347-8.
77. Nobukuni Y, Mitsubuchi H, Endo F, Akaboshi I, Asaka J, Matsuda I (1990) Maple syrup urine disease: Complete primary structure of the E1-beta subunit of human branched-chain alpha-ketoacid dehydrogenase complex deduced from the nucleotide sequence and a gene analysis of patients with this disease. J Clin Invest 86: 242-247. doi: 10.1172/JCI114690.
78. Ogier de Baulny H, Saudubray JM (2002) Branched-chain organic acidurias. Semin Neonatol 7(1): 65-74. doi: 10.1053/siny.2001.0087.
79. Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR (1998) Bidirectional modulation of insulin action by amino acids. JClin Invest 101: 1519-1529. doi: 10.1172/JCI1326.
80. Paxton R, Harris R (1982) Isolation of rabbit liver branched-chain α-keto dehydrogenase and regulation by phosphorylatio. J Biol Chem 257: 14433-14439.
81. Paxton R, Kuntz MJ, Harris R (1986) Phosphorylation sites and inactivation of branched-chain α-keto acid dehydrogenase from rat heart bovine kidney and rabbit liver kidney heart brain and skeletal muscle. Arch Biochem Biophys 244: 187-201. doi: 10.1016/ 0003-9861(86)90108-6.
82. Peinemann F, Danner DJ (1994) Maple syrup urine disease 1954-1993. J Inherit Metab Dis 17: 3-15. doi: 10.1007/BF00735389.
83. Pons G, Raefsky-Estrin C, Carothers DJ, et al (1988) Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component of human alpha-ketoacid dehydrogenase complexes. Proc Natl Acad Sci U S A 85: 1422-1426. doi: 10.1073/pnas.85.5.1422.
84. Popov KM, Zhao Y, Shimomura Y, Kuntz MJ, Harris RA (1992) Branched-chain alpha-ketoacid dehydrogenase kinase. Molecular cloning expression and sequence similarity with histidine protein kinases. J Biol Chem 267: 13127-13130.
85. Prasad VK, Kurtzberg J (2008) Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 41(2): 99-108. doi: 10.1038/sj.bmt.1705970.
86. Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJ (2002) Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol 17(4): 239-242. doi: 10.1007/s00467-001-0801-2.
87. Sakaguchi Y, Yoshino M, Aramaki S, et al (1986) Dihydrolipoyl dehydrogenase deficiency: A therapeutic trial with branched-chain amino acid restriction. Eur J Pediatr 145: 271-274. doi: 10.1007/BF00439399.
88. Sallan SE, Cottom D (1969) Peritoneal dialysis in maple syrup urine disease. Lancet 294(7635): 1423-1424. doi: 10.1016/S0140-6736(69)90961-1.
89. Saudubray JM, Ogier H, Charpentier C, et al (1984) Hudson memorial lecture. Neonatal management of organic acidurias. Clinical update. J Inherit Metab Dis 7(Supplement): 2-9.
90. Schadewaldt P, Wendel U (1997) Metabolism of branched-chain amino acids in maple syrup urine disease. Eur J Pediatr 156(Supplement 1): S62-6. doi: 10.1007/PL00014274.
91. Scherer SW, Otulakowski G, Robinson BH, Tsui L-C (1991) Localization of the human dihydrolipoamide dehydrogenase gene (DLD) to 7q31-q32. Cytogenet Cell Genet 56: 176-177. doi: 10.1159/000133081.
92. Schmid E, Schmid W, Jantzen M, Mayer D, Jastorff B, Schütz G (1987) Transcription activation of the tyrosine aminotransferase gene by glucocorticoids and cAMP in primary hepatocytes. Eur J Biochem 165(3): 499-506. doi: 10.1111/j.1432-1033.1987.tb11467.x.
93. Scriver CR, MacKenzie S, Clow CL, Delvin E (1971) Thiamine-responsive maple-syrup-urine disease. Lancet 297(7694): 310-312. doi: 10.1016/ S0140-6736(71)91041-5.
94. Scriver CR, Clow CL, George H (1985) So-called thiamin-responsive maple syrup urine disease: A 15-year follow-up of the original patient. J Pediatr 107: 763-765.
95. Shaag A, Saada A, Berger I, et al (1999) Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet 82: 177-182. doi: 10.1002/ (SICI)1096-8628(19990115)82:2<177::AID-AJMG15>3.0.CO;2-9.
96. Sharma AD, Cantz T, Vogel A, et al (2008) Murine embryonic stem cell-derived hepatic progenitor cells engraft in recipient livers with limited capacity of liver tissue formation. Cell Transplant 17(3): 313-323.
97. She P, Bronson SK, Vary TC, Carrel L, Hutson SM, Lynch CJ (2007a) Deletion of BCATm leads to loss TORC1 signaling in response to Leu and {alpha}-ketoisocaproate (KIC) but not insulin. FASEB J 21: 73816.
98. She P, Reid TM, Bronson SK, et al (2007b) Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 6: 181-194. doi: 10.1016/ j.cmet.2007.08.003.
99. Shimomura Y, Nanaumi N, Suzuki M, Popov KM, Harris RA (1990) Purification and partial characterization of branched-chain alpha-ketoacid dehydrogenase kinase from rat liver and rat heart. Arch Biochem Biophys 283: 293-299. doi: 10.1016/0003-9861(90)90645-F.
100. Silao CL, Padilla C, Matsuo M (2004) A novel deletion creating a new terminal exon of the dihydrolipoyl transacylase gene is a founder mutation of Filipino maple syrup urine disease. Mol Genet Metab 81(2): 100-104. doi: 10.1016/j.ymgme.2003.10.006.
101. Silberman J, Dancis J, Feignin I (1961) Neuropathological observations in maple syrup urine disease: Branched-chain ketoaciduria. Arch Neurol 5: 351-363.
102. Skvorak KJ, Homanics GE, Paul HS, et al (2008a) Amino acid and neurotransmitter abnormalities in murine intermediate maple syrup urine disease (iMSUD): Significant improvement of cerebral dopamine and serotonin deficiency with hepatocyte transplantation (HTx). In: Society for the Study of Inborn Errors of Metabolism Annual Symposium 2008, Lisbon, Portugal.
103. Skvorak KJ, Paul HS, Dorko K, et al (2008b) Hepatocyte transplantation (HTx) extends lifespan increases branched chain α-keto acid dehydrogenase (BCKDH) activity and improves amino acid profiles in a murine model of intermediate maple syrup urine disease (iMSUD). In: Society for the Study of Inborn Errors of Metabolism Annual Symposium 2008, Lisbon, Portugal.
104. Snyderman S (1988) Treatment outcome of maple syrup urine disease. Acta Paediatr Jpn 30: 417-424.
105. Snyderman SE, Norton PM, Roitman E, Holt LEJ (1964) Maple syrup urine disease with particular reference to dietotherapy. Pediatrics 34: 454-462.
106. Soemitro S, Block KP, Crowell PL, Harper AE (1989) Activities of branched-chain amino acid-degrading enzymes in liver from rats fed different dietary levels of protein. J Nutr 119(8): 1203-1212.
107. Strauss KA, Mazariegos GV, Sindhi R, et al (2006) Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant 6(3): 557-564. doi: 10.1111/ j.1600-6143.2005.01209.x.
108. Talbot D, Descombes P, Schibler U (1994) The 5′ flanking region of the rat LAP (C/EBP beta) gene can redirect high-level position-independent copy number-dependent expression in multiple tissues in transgenic mice. Nucleic Acids Res 22: 756-766. doi: 10.1093/ nar/22.5.756.
109. Van Koevering M, Nissen SL (1992) Oxidation of leucine and alpha-ketoisocaproate to β-hydroxy-β-methylbutyrate in vivo. Am J Physiol Endocrinol Metab 262: 27-31.
110. Waagepetersen HS, Sonnewald U, Schousboe A (2003) Compartmentation of glutamine glutamate and GABA metabolism in neurons and astrocytes: functional implications. Neuroscientist 9(5): 398-403. doi: 10.1177/ 1073858403254006.
111. Wajner M, Coelho DM, Barschak AG, et al (2000) Reduction oflarge neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease during crises. J Inherit Metab Dis 23: 505-512. doi: 10.1023/A:1005668431926.
112. Wang X, Chinsky JM, Costeas PA, Price SR (2001) Acidification and glucocorticoids independently regulate branched-chain alpha-ketoacid dehydrogenase subunit genes. Am J Physiol Cell Physiol 280(5): C1176-C1183.
113. Wellner D, Meister A (1981) A survey of inborn errors of amino acid metabolism and transport in man. Annu Rev Biochem 50: 911-968. doi: 10.1146/annurev.bi.50.070181.004403.
114. Wendel U, Langenbeck U, Lombeck I, Bremer HJ (1982) Exchange tranfusion in acute episodes of maple syrup urine disease - studies on branched-chain amino and keto acids. Eur J Pediatr 138: 293-296. doi: 10.1007/BF00442499.
115. Wendel U, Saudubray JM, Bodner A, Schadewaldt P (1999) Liver transplantation in maple syrup urine disease. Eur J Pediatr 158(Supplement 2): S60-64. doi: 10.1007/PL00014324.
116. Williams D (2008) US National Screening Status Report [website] 2008 Sept 16 [accessed 2008 Oct 1]; Available from: http://genes-r-usuthscsaedu/nbsdisorderspdf.
117. Wilson GJ, Wilson JM, Manninen AH (2008) Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age sex and training experience: A review. Nutr Metab (Lond) 5: 1. doi: 10.1186/1743-7075-5-1.
118. Wu JY, Kao HJ, Li SC, et al (2004) ENU mutagenesis identifies mice with mitochondrial branched-chain aminotransferase deficiency resembling human maple syrup urine disease. J Clin Invest 113: 434-440.
119. Yeaman S (1989) The 2-oxo acid dehydrogenase complexes: Recent advances. Biochem J 257: 625-632.
120. Yoshino M, Aoki K, Akeda H, et al (1999) Management of acute metabolic decompensation in maple syrup urine disease: A multi-center study. Pediatr Int 41(2): 132-137. doi: 10.1046/j.1442-200X.1999.4121044.x.
121. Yudkoff M (1997) Brain metabolims of branched-chain amino acids. Glia 21: 92-98. doi: 10.1002/ (SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W.
122. Zhang B, Crabb DW, Harris RA (1988) Nucleotide and deduced amino acid sequence of the E1-alpha subunit of human liver branched-chain alpha-ketoacid dehydrogenase. Gene 69: 159-164. doi: 10.1016/ 0378-1119(88)90390-3.
123. Zhang B, Healy PJ, Zhao Y, Crabb DW, Harris R (1990) Premature translation termination of the pre-E1alpha subunit of the branched chain alpha-ketoacid dehydrogenase as a cause of maple syrup urine disease in polled Hereford calves. J Biol Chem 265(5): 2425-2427.
124. Zielke HR, Huang Y, Tildon JT, Zeilke CL, Baab PJ (1996) Elevation of amino acids in the interstitial space of the rat brain following infusion of large neutral amino and keto acids by microdialysis: alpha-ketoisocaproate infusion. Dev Neurosci 18: 420-425. doi: 10.1159/ 000111436.
125. Zinnanti WJ, Lazovic J, Griffin K, et al (2009) Dual mechanisms of brain injury and novel treatment in maple syrup urine disease. Brain (in press).